BNP Paribas Financial Markets
MGX icon

BNP Paribas Financial Markets’s Metagenomi Therapeutics MGX Stock Holding History

BNP Paribas Financial Markets’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$246 Sell
207
-100
-33% -$134 ﹤0.01% 5742
2026
Q1 		$411 Hold
307
– – ﹤0.01% 5560
2025
Q4 		$497 Sell
307
-14,864
-98% -$32.2K ﹤0.01% 5479
2025
Q3 		$36K Buy
15,171
+14,389
+1,840% +$29.2K ﹤0.01% 4729
2025
Q2 		$1.16K Buy
782
+1
+0.1% +$2 ﹤0.01% 5129
2025
Q1 		$1.06K Sell
781
-1,723
-69% -$4.11K ﹤0.01% 5063
2024
Q4 		$9.04K Sell
2,504
-10,295
-80% -$24.8K ﹤0.01% 4857
2024
Q3 		$27.8K Buy
12,799
+7,256
+131% +$25.2K ﹤0.01% 3710
2024
Q2 		$22.6K Buy
+5,543
New +$38.1K ﹤0.01% 3625

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BNP Paribas Financial Markets's MGX Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Metagenomi Therapeutics (MGX) stake by 33% in Q2 2026, selling an estimated $134 and leaving 207 shares worth $246. The position accounts for ﹤0.01% of the portfolio, ranked #5742.

BNP Paribas Financial Markets first reported a position in MGX in Q2 2024 and has held it in 9 quarters since. The position peaked at $36K in Q3 2025. 33 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • BNP Paribas Financial Markets held 207 shares of Metagenomi Therapeutics worth $246 as of Q2 2026.
  • BNP Paribas Financial Markets sold 100 Metagenomi Therapeutics shares in Q2 2026, an estimated $134.
  • Metagenomi Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5742 holding.
  • BNP Paribas Financial Markets first reported a position in Metagenomi Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • BNP Paribas Financial Markets's Metagenomi Therapeutics position peaked at $36K in Q3 2025.
  • 33 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.